[1] World Health Orgnization. Global hepatitis report-2017. https://wwwwhoint/hepatitis/publications/global-hepatitis-report2017/en/. 2017. Acessed June 02, 2020.
[2] Buti M, Craxi A, Foster GR, et al. Viral hepatitis elimination: Towards a hepatitis-free world. J Hepatol,2022,77(5): 1444-1447.
[3] Cui F, Woodring J, Chan P, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol,2018,47(5): 1529-1537.
[4] Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ,2019,97(3):230-238.
[5] 饶慧英,魏来.从可治疗到可治愈再到消除—丙型肝炎诊断和治疗研究近十年进展. 中华肝脏病杂志,2021,29(2): 102-107.
[6] Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol,2022,7(9): 796-829.
[7] World Health Organization. Interim guidance for country validation of viral hepatitis elimination. https://www.who.int/publications/i/item/9789240028395. Accessed Jan 02,2023.
[8] Polaris Observatory HCVC. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol,2022,7(5): 396-415.
[9] Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis,2022,122: 476-485.
[10] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志,2022,30(2): 131-136.
[11] 王皓,单姗,尤红,等.抗病毒治疗适应证变化对提高慢性乙型肝炎治疗率的影响. 临床肝胆病杂志,2022,38(6): 1269-1274.
[12] 贾继东.我国慢性乙型肝炎防控所取得的成就与未来挑战.中国临床医生杂志,2022,50(10): 1135-1136.
[13] Li M, Zhao L, Zhou J, et al. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. Lancet Reg Health West Pac,2021,61261216:100249.
[14] Zhao X, Li M, Wang H, Xu X, Wu X, Sun Y, et al. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. J Clin Transl Hepatol,2022,10(3):420-428.
[15] Li M, Kong YY, Wu SS, et al. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. J Dig Dis, 2019,20(9):467-475.
[16] 孟彤彤, 缪宁, 郑徽,等. 中国15～69岁乙型肝炎表面抗原阳性者对自身感染状态的知晓率及其影响. 中华肝脏病杂志, 2022,30(5): 534-540.
[17] https://cdafound.org/%20polaris-countries-dashboard/Acessed Jan, 2023.
[18] 中联肝健康促进中心,中华医学会肝病学分会,中华医学会检验医学分会,等.中国丙型病毒性肝炎院内筛查管理流程(试行).中华肝脏病杂志,2021, 29(4): 315-329.
[19] Waked I, Esmat G, Elsharkawy G, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med,2020,382(12): 1166-1174.
[20] 中国肝炎基金会-海南省消除肝炎危害行动在海口启动http://www.cfhpc.cn/Article/ArticleDetail?ArticleId=40cb4391-50d4-45d4-aaaa-509fbd198f9f/Acessed Dec 2021.
[21] 福建省乙型肝炎病毒感染者规范治疗项目试点工作启动https://wjw.fujian.gov.cn/xxgk/gzdt/wsjsyw/202210/t20221021_6021105.htm./Acessed Oct, 2022. |
